1,195 research outputs found
Concurs adequació nau central Fabra i Coats
No full textProjecte presentat al Contracte de Serveis pel “Projecte bàsic i executiu, Direcció d’obra i estudi de Seguretat i Salut de les obres d’adequació de la nau central del recinte de Fabra i Coats per a contenidor de producció cultural”No es va saber la valoració exactePostprint (published version
Concurs adequació nau central Fabra i Coats
No full textProjecte presentat al Contracte de Serveis pel “Projecte bàsic i executiu, Direcció d’obra i estudi de Seguretat i Salut de les obres d’adequació de la nau central del recinte de Fabra i Coats per a contenidor de producció cultural”No es va saber la valoració exactePostprint (published version
Rowell, Coats and Students
No full textActress and author Victoria Rowell spoke to students, staff and faculty on her memoir, *The Women Who Raised Me.* Rowell poses here with Interim Department Head of MSU\u27s Curriculum & Instruction Linda Coats (l) and students
Coats’-type changes in a retinitis pigmentosa family
No full textAim: A dominant retinitis pigmentosa (RP) family of four generations with a follow-up of 15 years, including 2 brothers
of generation IV affected by Coats-type changes, is herein described.
Methods: Retrospective, single-center case series. Eleven family
members, 6 of whom affected by RP, were examined using visual acuity tests, ophthalmoscopy, Goldmann visual field, electroretinography, and atipical coherence tomography.
Results and Conclusion: In this family, only two out of eleven examined patients had RP with Coats’-type changes. Review of the literature disclosed four other familial cases of Coats-type retinitis pigmentosa
Recommended from our members
Coats plus in prematurity
No full textCoats plus syndrome or cerebroretinal microangiopathy with calcifications and cysts (CMCC) is an exceedingly rare autosomal recessive disorder that predominantly affects the microvasculature in the retina, brain, bones, and gastrointestinal system. Unlike Coats disease, CMCC is bilateral and affects multiple organ systems.
Case report
We report the case of two brothers with Coats Plus syndrome who presented with variable phenotypic expression. One sibling (Patient 1) was thought to have atypical retinopathy of prematurity and was only diagnosed with Coats plus after his older brother (Patient 2) presented with a seizure and a left upper extremity tremor at 4 years of age. The CTC1 mutation was confirmed in both patients. Aggressive treatment with laser photocoagulation and intravitreal bevacizumab dramatically improved the retinal vascular and exudative changes.
Coats Plus syndrome can have a variable phenotypic presentation, including retinal vascular findings. This rare genetic disease should be in the differential diagnosis in patients who present with atypical retinal pathology, including Retinopathy of Prematurity, Familial Exudative Vitreoretinopathy, or Coats disease associated with non-specific multiorgan abnormalities
Coats’ Disease
No full textCoats’ disease is one of the exudative retinopathies, commonly presented in childhood. Differentiation of Coats’ disease from retinoblastoma is vital especially during the first years of life prior to commencing treatment. Early stages of the disease can be controlled with ablative therapies such as laser photocoagulation or cryotherapy; however, as the disease progresses to more advanced stage, transscleral drainage of subretinal fluid (SRF) may be needed to control the disease activity. Transscleral drainage of SRF increases the effectiveness of ablative therapies by attaching the retina. Recently, pars plana vitrectomy has been found useful in advanced Coats’ disease. Removal of vitreous and concomitant vitreoretinal tractional membranes can reduce the need for further ablative treatment and prevent from the development of subsequent tractional retinal detachment. Anti-VEGF agents can be used as an adjunct to ablative therapies in cases where considerable leakage from abnormal vessels is present. Visual prognosis is mainly dependent on foveal involvement. Subfoveal exudation may transform into subfoveal nodule which indicates poor visual prognosis. In advanced disease, visual prognosis is unfortunately quite poor; therefore, the goal of the treatment is to preserve globe anatomically without causing any further disturbance to the patient in such advanced cases. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: Update 2023
No full textAbstract The Journal of Cachexia, Sarcopenia and Muscle (JCSM) aims to publish articles with relevance to wasting disorders and illnesses of the muscle in the broadest sense. In order to avoid publication of inappropriate articles and to avoid protracted disputes, the Editors have established ethical guidelines that detail a number of regulations to be fulfilled prior to submission to the journal. This article updates the principles of ethical authorship and publishing in JCSM and its daughter journal JCSM Rapid Communication. We require the corresponding author, on behalf of all co‐authors, to certify adherence to the following principles: All authors listed on a manuscript considered for publication have approved its submission and (if accepted) approve publication in the journal; Each named author has made a material and independent contribution to the work submitted for publication. No person who has a right to be recognized as author has been omitted from the list of authors on the submitted manuscript; The submitted work is original and is neither under consideration elsewhere nor that it has been published previously in whole or in part other than in abstract form; All authors certify that the submitted work is original and does not contain excessive overlap with prior or contemporaneous publication elsewhere, and where the publication reports on cohorts, trials, or data that have been reported on before the facts need to be acknowledged and these other publications must be referenced; All original research work has been approved by the relevant bodies such as institutional review boards or ethics committees; All relevant conflicts of interest, financial or otherwise, that may affect the authors' ability to present data objectively, and relevant sources of funding of the research in question have been duly declared in the manuscript; All authors certify that they will submit the original source data to the editorial office upon request; Authors who have used artificial intelligence, language models, machine learning, or similar technologies need to provide a written statement – as part of the manuscript – that details the use of the respective technology; none of the aforementioned technologies can be listed as an author; The manuscript in its published form will be maintained on the servers of the journal as a valid publication only as long as all statements in these guidelines remain true. If any of the aforementioned statements ceases to be true, the authors have a duty to notify as soon as possible the Editor‐in‐Chief of the journal, so that the available information regarding the published article can be updated and/or the manuscript can be withdrawn
Disappearing signs. Can the changes in The Polish chivalric coats-of-arm s be traced in medieval sources?
No full textThe paper presents an overview of current papers(but it reminds us also of fi ndings of prewar researchers) about coats-of-arms of small chivalric clans, rarely present in sources. It also contains some fi ndings made by the author himself, mainly about Prus, Chmara and Zgraja coats-of-arms. The intent of the author was also a limited sources study refl ec-tion on the coats-of-arms, about which there is lack of information concerning their shape and probable genetical relationship with other coats-of-arms. The following coats-of-arms or their callings were mentioned: Kliza, Wiza, Moszczenica, Calina, Wazanki, Piękostki, Ulina, Owada, Czawuja, Kołmasz, Prus I (Turzyna), Prus II (Wilczekosy), Glezyna, Lary-sza, Ogniwo, Zarosie, Chmara, Zgraja, Goljan. Most of them turned out to equate with other, better known coats-of-arms, or strove for that kind of equation. All this makes the structure of polish medieval society and the rules of that society more clea
Efeitos de diferentes processamentos de Buffy Coats na função de monócitos
No full textMonócitos são leucócitos mononucleares fagolíticos circulantes com a capacidade de se diferenciarem em macrófagos, desempenhando múltiplas funções no sistema imune. Os monócitos têm sido descritos como células apresentadoras de antigénios (APC) competentes, uma vez que são capazes de adquirir, preservar e processar antigénios em tecidos periféricos e transportá-los para a zona das células T nos nódulos linfáticos, onde encontram células T cognatas.
As células invariantes NKT (iNKT) são células T restritas a CD1d caracterizadas pela expressão de um TCR semi-invariante, uma vez que contém uma cadeia α invariável. Este TCR especial permite o reconhecimento de um vasto espectro de antigénios lipídicos. O antigénio protótipo usado para ativação de iNKT é a α-Galactosilceramida (αGalCer). Após a estimulação por parte do antigénio, as células iNKT rapidamente produzem grandes quantidades de citocinas.
O Buffy Coat é um produto do processamento do sangue total e consiste numa unidade residual, contudo enriquecida em leucócitos. O Buffy Coat é uma fonte de células, nomeadamente monócitos, que está disponível diariamente para utilização em investigação. De acordo com o intervalo de tempo entre a colheita e o processamento da dádiva de sangue, os Buffy Coats são processados por dois protocolos distintos dando origem a: Buffy Coats processados em sangue fresco (Fresh Blood), em que a colheita e o processamento ocorrem no mesmo dia; ou Buffy Coats processados em sangue de pernoite (Overnight) onde o processamento do sangue total só ocorre no dia seguinte à colheita.
Esta tese tem como objetivo avaliar se as diferenças no tempo de processamento de Buffy Coats poderão ter impacto na viabilidade, no fenótipo e na função dos monócitos. Em particular, a função dos monócitos como célula apresentadora de antigénios foi investigada. Como CD1d é uma molécula apresentadora de antigénio não polimórfica, ao contrário das moléculas HLA altamente polimórficas, a apresentação de antigénios lipídicos (αGalCer e α-GalGalCer) a células iNKT restritas a CD1d foi avaliada. Foram analisados Buffy Coats com diferentes tempos de processamento e diferentes tempos de espera nomeadamente: Buffy Coat processado em Fresh Blood e que aguardou 24h para ser analisado; Buffy Coat processado em Overnight que esperou 0h para ser analisado e Buffy Coat processado em Fresh Blood que esperou 48h pelos ensaios. Os ensaios de ativação realizados levaram à conclusão de que os monócitos provenientes de Buffy Coats processados em Fresh Blood e que esperam 24h para ser analisados têm uma melhor capacidade de ativar células iNKT do que aqueles que advêm de Buffy Coats processados em Overnight e que esperam 0h para serem analisados. Esta diferença não pode ser justificada por diferenças na viabilidade dos monócitos, nem pela expressão à superfície de CD1d ou pelo estado de ativação apurado pela expressão à superfície de CD40 e CD80 quando comparados os Buffy Coats processados em tempos distintos. Tendo em conta estas diferenças, foi investigado se o aumento do tempo de espera para o ensaio de ativação se poderia traduzir numa melhor capacidade de apresentar antigénios lipídicos por parte dos monócitos. Foi verificado que a capacidade de apresentação de antigénios por parte dos monócitos de Buffy Coats processados em Fresh Blood que aguardam 48h não supera a capacidade de ativar iNKT pelos monócitos de Buffy Coats processados em Fresh Blood que esperam 24h pelas experiências.
Com o objetivo de tentar explicar as diferenças na capacidade de apresentação de antigénios lipídicos por parte dos monócitos isolados dos Buffy Coats com diferentes tempos de processamento, analisou-se a expressão de genes associados à ativação de monócitos ou genes importantes para a apresentação de antigénios. Não foram observadas diferenças na expressão dos genes IL-6, IL-8, IL12p-40, IL-18 e XBP1s entre os monócitos de Buffy Coats processados em Fresh Blood que esperam 24h para serem analisados e os monócitos de Buffy Coats processados em Overnight que aguardam 0h para serem analisados. Monócitos provenientes de Buffy Coats processados em Fresh Blood que aguardam 48h até serem analisados tiveram maior expressão dos genes IL-6 e IL-18 quando comparados aos monócitos de Buffy Coats processados em Overnight que esperam 0h para serem analisados.
Ainda foi realizada a ativação de monócitos com Lipopolissacarídeo (LPS) para avaliar se as diferenças observadas na capacidade de ativação das iNKT por monócitos dos diferentes Buffy Coats também seriam observadas ao usar um estímulo mais geral como o LPS. Os resultados mostram que a capacidade de ativar células iNKT e a ativação com LPS podem estar relacionadas, mas mais experiências são necessárias para obter conclusões mais fiáveis.
Além disso, colocou-se a hipótese de que as diferenças na capacidade de ativação de células iNKT demonstradas pelos monócitos provenientes de dois tipos de Buffy Coats poderiam dever-se a diferentes capacidades de captação do antigénio lipídico. Para testar esta hipótese, monócitos foram incubados com αGalCer fluorescente (αGalCer-BODIPY) e a captação de αGalCer pelos monócitos foi quantificada por citometria de fluxo. Quatro experiências foram realizadas, mas os resultados não mostraram uma diferença clara na captação de αGalCer entre monócitos dos dois tipos de Buffy Coats que justificassem as diferenças observadas na capacidade de ativação de iNKT.
Esta tese contribui para uma melhor caracterização dos monócitos isolados de Buffy Coats. Este trabalho indica que os diversos protocolos de processamento de Buffy Coats influenciam as funções dos monócitos como APC. Os resultados mostram que monócitos de Buffy Coats processados em Fresh Blood que esperam 24h têm melhor capacidade de ativar células iNKT. Portanto, o tipo de protocolo para o processamento de Buffy Coats deve ser cuidadosamente considerado na investigação diária, uma vez que pode levar a resultados diferentes.Monocytes are circulating mononuclear phagocytes with the capacity to differentiate into macrophages, carrying out multiple functions in the immune system. Monocytes have been described as competent antigen-presenting cells (APC), as they are able to acquire, preserve and process antigens in peripheral tissues and transport them into the T cell zone of the draining lymph nodes where they encounter cognate T cells.
Invariant NKT cells (iNKT) are CD1d-restricted T cells characterized by the expression of a semi-invariant TCR, as it contains an invariable α chain. This special TCR enables the recognition of a vast spectrum of lipid antigens. The prototype antigen used for activation of iNKT is α-Galactosylceramide (αGalCer). Upon antigen stimulation, iNKT cells rapidly produce large amounts of cytokines.
The Buffy Coat is a product of the whole blood processing and consists of a residual but leukocyte enriched unit. The Buffy Coat is a source of cells, namely monocytes, that is daily available for research use. According to the time interval between collection and processing of the blood donation, Buffy Coats are processed by two different protocols giving rise to: Fresh Blood Buffy Coats, in which the blood collection and processing occurs in the same day; or Overnight Buffy Coats where the processing of the whole blood only happens in the following day of the blood harvest.
This thesis aimed to assess if the differences in the processing time of Buffy Coats could have an impact on monocyte viability, phenotype and function. In particular, monocyte function as an antigen-presenting cell was investigated. As CD1d is a non-polymorphic antigen-presenting molecule in opposition to the high polymorphic HLA molecules, lipid antigen (αGalCer and α-GalGalCer) presentation to CD1d-restricted iNKT cells was investigated. Buffy Coats with different processing and waiting times were analysed: Buffy Coat Fresh Blood processed which waited 24h to be analysed; Buffy Coat Overnight processed which waited 0h to be analysed and Buffy Coat Fresh Blood processed that waited 48h for the assays.
We found that monocytes from Buffy Coats Fresh Blood processed 24h analysed have a better capacity to activate iNKT than those from Buffy Coats Overnight processed 0h analysed. This difference was not justified by different monocyte viability, CD1d cell surface expression, or activation state measured by CD40 and CD80 cell surface expression comparing the different time processed Buffy Coats. Considering these differences, we investigated whether increasing the waiting time for the activation assay could translate into a better capacity to present lipid antigens by the monocytes. We found that the antigen presenting capacity of monocytes from Buffy Coats Fresh Blood processed that waits 48h to be analysed does not exceed the capacity of monocytes from the Buffy Coats Fresh Blood processed 24h analysed in iNKT activation.
In order to try to explain the different capacity of monocytes isolated from Buffy Coats with different processing times in lipid antigen presentation, the expression of genes associated with monocyte activation or genes important for antigen presentation was investigated in monocytes isolated from the three different Buffy Coats. No differences in expression of IL-6, IL-8, IL12p-40, IL-18 and XBP1s genes were observed between monocytes from Buffy Coats Fresh Blood processed 24h analysed and monocytes from Buffy Coats Overnight processed 0h analysed. Monocytes from Buffy Coats Fresh Blood processed 48h analysed had higher expression of the genes IL-6 and IL-18 when compared to monocytes from Buffy Coats Overnight processed 0h analysed.
Monocyte activation assays with Lipopolysaccharide (LPS) were also performed to assess whether the differences observed in the capacity to activate iNKT by monocytes from different Buffy Coats were also observed when using a more general stimulus as LPS. Our results show that capacity to activate iNKT and activation with LPS might be related but more experiments are needed to retrieve more reliable conclusions.
In addition, we postulated that the differences in the capacity to activate iNKT demonstrated by the monocytes from the two Buffy Coats types could be due to different capacity to uptake the lipid antigen. To test this hypothesis monocytes were incubated with fluorescent αGalCer (αGalCer-BODIPY) and αGalCer uptake by monocytes was quantified by flow cytometry. Four experiments were carried out, the results did not show a clear difference in αGalCer uptake between monocytes from the two types of Buffy Coats that justified the differences observed in the capacity to activate iNKT.
This thesis contributes to a better characterization of the monocytes isolated from Buffy Coats. This work indicates that the various protocols of processing of the Buffy Coats influence monocytes’ function as APC. Our results show that monocytes from Buffy Coats Fresh Blood processed that waits 24h to the activation assay have a better capacity to activate iNKT cells. Hence, the type of protocol for Buffy Coats processing should be carefully considered in daily research, since it may lead to different outcomes.Mestrado em Biomedicina Molecula
Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease
No full text: The aim of this retrospective study was to describe the vascular features in eyes with Coats disease, using optical coherence tomography angiography (OCTA), at baseline and after 3 monthly intravitreal injections of ranibizumab. Fifteen eyes of 15 consecutive patients affected by Coats' disease were recruited in this study. All patients underwent the best-corrected visual acuity (BCVA) evaluation, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), multicolor imaging, structural Spectral Domain (SD)-OCT and OCTA at baseline and 1 month after the third monthly ranibizumab injection (loading phase). Fifteen patients completed the study, of whom nine were males and six females. Mean age was 20.4 ± 2 years. BCVA was 0.46 ± 0.11 logMar and 0.47 ± 0.12 logMar at baseline and after treatment, respectively (p = 0.164). SD-OCT revealed no significant decrease in central macular thickness (486.33 μm ± 93.37 at baseline vs. 483.4 μm ± 80.97 after treatment; p = 0.915). The subretinal exudates persisted in macular region after intravitreal injections. OCTA showed a general vascular rarefaction in superficial capillary plexus (SCP), deep capillary plexus (DCP), and choriocapillary (CC) that did not change after loading phase. This study showed no functional and vascular improvement following 3 monthly ranibizumab injections. OCTA, non-invasive technique, could be useful during follow up of these patients and provide a better understand of pathogenesis of this disorder
- …
